Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I

Marielle Brockhoff,1 Nathalie Rion,2 Kathrin Chojnowska,2 Tatwana Wiktorowicz,1 Christopher Eickhorst,2 Beat Erne,1 Stephan Frank,3 Corrado Angelini,4 Denis Furling,3 Markus A. Ruegg,2 Michael Sinnreich,1 and Perrine Castets1,2

1Neuromuscular Research Group, Departments of Neurology and Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland. 2Biozentrum, University of Basel, Basel, Switzerland. 3Institute of Pathology, Division of Neuropathology, University of Basel, University Hospital Basel, Basel, Switzerland. 4Fondazione San Camillo Hospital IRCCS, Venice Lido, Italy. 5Sorbonne Universités, University Pierre and Marie Curie (UPMC) Paris 06, Inserm, CNRS, Centre de Recherche en Myologie, Institut de Myologie, GH Pitie-Salpetriere, Paris, France.

Myotonic dystrophy type I (DM1) is a disabling multisystemic disease that predominantly affects skeletal muscle. It is caused by expanded CTG repeats in the 3′-UTR of the dystrophia myotonica protein kinase (DMPK) gene. RNA hairpins formed by elongated DMPK transcripts sequester RNA-binding proteins, leading to mis-splicing of numerous pre-mRNAs. Here, we have investigated whether DM1-associated muscle pathology is related to deregulation of central metabolic pathways, which may identify potential therapeutic targets for the disease. In a well-characterized mouse model for DM1 (HSALR mice), activation of AMPK signaling in muscle was impaired under starved conditions, while mTORC1 signaling remained active. In parallel, autophagic flux was perturbed in HSALR muscle and in cultured human DM1 myotubes. Pharmacological approaches targeting AMPK/mTORC1 signaling greatly ameliorated muscle function in HSALR mice. AICAR, an AMPK activator, led to a strong reduction of myotonia, which was accompanied by partial correction of misregulated alternative splicing. Rapamycin, an mTORC1 inhibitor, improved muscle relaxation and increased muscle force in HSALR mice without affecting splicing. These findings highlight the involvement of AMPK/mTORC1 deregulation in DM1 muscle pathophysiology and may open potential avenues for the treatment of this disease.

Introduction

Myotonic dystrophy type I (DM1; OMIM #160900) is a multisystemic neuromuscular disorder, which represents the most common form of muscular dystrophy in adults (1). In particular, DM1 patients suffer from muscle wasting, weakness, and myotonia. DM1 is an autosomal dominant disease caused by an expansion of unstable CTG repeats located within the 3′-UTR of the dystrophia myotonica protein kinase (DMPK) gene. Toxic expanded transcripts containing RNA hairpins formed by the triplet repeats accumulate as RNA foci in the nuclei of affected cells (2, 3). These mutant transcripts are thought to sequester RNA-binding proteins, such as muscleblind-like 1 (MBNL1), and to increase CUG triplet repeat RNA-binding protein 1 (CUGBP1) levels. The resulting splicing defects are considered the primary cause of DM1 symptoms (4–6). HSA18 mice, which carry a CTG repeat expansion in the human skeletal actin (HSA) gene, constitute a well-characterized mouse model for DM1 (5). These mice express (CUG)n-expanded transcripts specifically in skeletal muscle and reiterate the dystrophic phenotype and myotonic discharges observed in muscle of patients. HSA18 mice also recapitulate DM1 molecular characteristics such as foci accumulation, MBNL1 sequestration, and splicing abnormalities (5, 7, 8). Therapeutic strategies have mainly focused on targeting DM1-associated mis-splicing and mRNa toxicity (9–11), although a more complete understanding of pathogenic pathways would clearly be of interest for the development of alternative or additional therapeutic options.

Recently, deregulation of cellular processes and signaling pathways important for maintaining proper muscle homeostasis has been reported in DM1. This includes abnormal activation of the ubiquitin-proteasome system and increased autophagic flux, which were both related to muscle atrophy and weakness in DM1 (12–14). In parallel, perturbation in the PKB/Akt pathway may arise from altered expression of the insulin receptor, which correlates with glucose intolerance in DM1 patients (15). Although PKB/Akt deregulation has been reported in Dmpk-deficient mice (16), in DM1 flies (13), and in DM1 human neural stem cells (17), contradictory results have been obtained in human muscle cells (18, 19).

To obtain further insight into the pathomechanisms associated with the disease, we investigated whether deregulated metabolic pathways may be involved in muscle alterations in DM1. We uncovered that muscles from HSA18 mice do not efficiently respond to fasting by displaying impaired activation of AMPK and delayed inhibition of the mTOR complex 1 (mTORC1) pathway. Moreover, we observed mild perturbations of the autophagic flux in both HSA18 muscle and myotubes from DM1 patients, which may arise from AMPK/mTORC1 deregulation. Importantly, we established that treatments normalizing these pathways improved

Conflict of Interest: M. Sinnreich owns shares of Novartis and is co-inventor on a patent application for drug discovery in DM1 (EP 16/162212.7). M. Sinnreich’s institution (University Hospital Basel) has received research support from CSL Behring and Roche, not in relation to this study. C. Angelini is part of the European Board of Genzyme-Sanofi.

Submitted: July 19, 2016. Accepted: November 17, 2016.

skeletal muscle strength and strongly reduced the myotonia in HSA<sup>LR</sup> mice. Our data provide evidence for the pathological role of metabolic pathways in DM1 and may open interesting avenues for alternative therapeutic strategies for the disease.

**Results**

**AMPK and mTORC1 pathways are deregulated in HSA<sup>LR</sup> muscle.** To identify pathomechanisms involved in DM1-related muscle alterations, we examined the potential deregulation of metabolic pathways in HSA<sup>LR</sup> mice (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI89616DS1). To this purpose, the activation state of key proteins was compared in muscle from 2-month-old mice analyzed in fed conditions or subjected to a physiological stimulus like fasting (20). No major difference was observed in the activation state of AMPK, PKB/Akt, and mTORC1 pathways in muscle from fed mutant and control mice, as reflected by the similar phosphorylation levels of AMPK (AMPK γ<sup>172</sup>), PKB/Akt (Akt γ<sup>473</sup>), and the mTORC1 targets ribosomal protein S6 kinase (p70S6K γ<sup>389</sup>) and S6 ribosomal protein (S6 γ<sup>235/236</sup> and S6 γ<sup>240/244</sup>) (Figure 1, A and B). After 24 hours of starvation, HSALR mice showed impaired activation of the AMPK pathway, as revealed by the reduced levels of AMPK γ<sup>172</sup> in tibialis anterior (TA) mutant muscle (Figure 1A). Regardless of the nutritional status, protein expression of the known AMPK regulatory kinases

Figure 1. AMPK and mTORC1 pathways do not respond to starvation in HSA<sup>LR</sup> muscle. (A and B) Two-month-old HSA<sup>LR</sup> and control (Ctrl) mice were examined in fed conditions and after 24 hours of starvation (St24). Immunoblots for phospho- (P) and total proteins of the AMPK (A) and mTORC1 (B) pathways reveal reduced AMPK activation and increased phosphorylation of some mTORC1 targets upon starvation in mutant muscle. Samples were run on the same gel but were noncontiguous. Protein quantification is given for AMPK γ<sup>172</sup> (Fed, n = 4 Ctrl and 3 HSA<sup>LR</sup>), CaMKII γM, Akt γ<sup>473</sup>, mTOR γ<sup>2448</sup> (Fed, n = 3; St24, n = 4), and S6 γ<sup>235/236</sup> (Fed, n = 3; St24, n = 7 Ctrl and 6 HSA<sup>LR</sup>). Data are relative to fed control mice and are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, 2-way ANOVA with Tukey’s multiple comparisons test correction. (C) Immunostaining on muscle cross sections from fed and starved (St24) HSA<sup>LR</sup> and control (Ctrl) mice shows high levels of phospho-S6 in mutant muscle upon starvation. Scale bar: 100 μm.
from muscles with a constant activation (TSCmKO; ref. 27) or deple-
tion (RAmKO; ref. 28) of mTORC1 (Supplemental Figure 1D). Nota-
bly, no major change in the phosphorylation of mTOR was observed
in mutant and control muscles from fed versus starved mice (Fig-
ture 1B). Moreover, upon starvation, changes in 4E-BP1 levels were
similar between HSALR and control muscles (Figure 1B), consistent
with previous reports indicating differential regulation of mTORC1
targets (29). Interestingly, mTORC1 deregulation was not related to
abnormal activity of PKB/Akt, since levels of the active phosphory-
lated form of PKB/Akt were efficiently decreased upon starvation in
mutant mice (Figure 1B). Accordingly, we did not detect any changes
in the splicing (exon 11, mis-spliced in DM1 patients) or expression of
the gene encoding insulin receptor (Insr) in TA muscle from 2-month-
old HSALR mice (Supplemental Figure 1E). Moreover, mTORC1 and
AMPK activation state in nonmuscle tissue, such as liver, was similar
in control and mutant mice (Supplemental Figure 1F), indicating that
deregulation of these pathways is confined to skeletal muscles, which
specifically express (CUG)n-expanded transcripts.

In an attempt to normalize mTORC1/AMPK pathways, con-
trol and HSA LR mice were subjected to starvation for 45 hours.
Mutant mice lost less weight than controls after prolonged star-
vation (Supplemental Figure 2). Moreover, upon 45 hours of star-
vation, phosphorylation of p70S6K and S6 was detected upon
muscles with a constant activation (TSCmKO; ref. 27) or deple-
tion (RAmKO; ref. 28) of mTORC1 signaling upon 45 hours of starvation (St45, A) and with metformin (MetF, B) or rapamy-
cin (Rapa, C) treatment in muscle from HSA LR mice. AMPK activation shows a trend toward increase in mutant muscle with metformin
treatment (B). Samples were run on the same gel but were noncontiguous. Protein quantification is shown for AMPK(Thr172) and 4E-BP1
(Fed, n = 3; St45, n = 4 Ctrl and 3 HSA LR; Veh [B], n = 3; MetF, n = 4; Veh [C], n = 4 Ctrl and 3 HSA LR; Rapa, n = 3 per genotype). Data are
relative to fed (A) or vehicle-treated (B and C) control mice and are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, 2-way ANOVA with
Tukey’s multiple comparisons test correction.
and does not involve ERK/p90S6K, which can also phosphorylate S6 at Ser235/6 (30). Levels of AMPK P172 remained unchanged in rapamycin-treated mice (Figure 2C). Although no obvious change was detected in AMPK-dependent phosphorylation of TSC2 (TSC2P1387), an upstream inhibitor of mTORC1 (Figure 1B), these results suggest that AMPK deregulation may primarily be responsible for the defective response to starvation and for mTORC1 signaling perturbation in HSALR muscle.

Autophagic flux is perturbed in HSALR muscle. It is well established that mTORC1 and AMPK are key regulators of autophagy and that perturbation of their activities can lead to severe tissue alterations, especially in skeletal muscle (31–33). To determine whether the expression of the CUG repeats impairs the autophagy process, we

Figure 3. HSALR muscles show mild deregulation of the autophagic flux. (A) Immunoblots for autophagy-related proteins show accumulation of autophagic substrates in HSA15 TA muscle in fed conditions. A reduced LC3I-to-LC3II switch is observed in mutant muscle upon 24 hours of starvation (St24), compared with control (Ctrl). Samples were run on the same gel but were noncontiguous. (Fed, n = 3; St24, n = 7 Ctrl and 6 HSA15 for LC3 ratio, n = 4 for p62.) For LC3I and LC3II levels, see Supplemental Figure 3A. (B) HSA15 mice expressing GFP-LC3 display increased number of GFP-positive puncta in TA muscle compared with control (Ctrl) in fed conditions (n = 3 Ctrl and 4 HSA15), but reduced accumulation after 24 hours of starvation (St24, n = 3). Scale bar: 50 μm; 10 μm for insets. A volume unit (vol) corresponds to 2.8 × 103 μm³. (C) Treatment with colchicine (Colch) leads to milder changes in LC3II levels in TA muscle from fed and starved HSA15 mice, compared with control (Ctrl) mice. For LC3II/LC3I quantification, see Supplemental Figure 3C. (D) Immunostaining of muscle sections from starved control (Ctrl) and HSALR mice reveals no major accumulation of p62 or ubiquitinated proteins in mutant muscle. Scale bar: 100 μm. Data are relative to control fed mice and represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, 2-way ANOVA with Tukey’s multiple comparisons test correction.
assessed the ability of HASL muscle to induce autophagy when the mice were subjected to starvation. First, we evaluated levels of the soluble (LC3I) and autophagosome-associated (LC3II) forms of the widely used LC3B (MAP1LC3 for microtubule-associated protein light chain 3) autophagy marker. The amount of LC3II correlates with the intracellular accumulation of autophagic vesicles (34). Under fed conditions, LC3II levels were increased, although not significantly, in mutant muscle, which reflects either a slight increase in autophagy induction or a mild defect in the degradation steps (Figure 3A and Supplemental Figure 3A). After 24 hours of starvation, a clear switch from LC3I to LC3II occurred in control muscle, while HASL muscle displayed reduced changes in LC3 levels and LC3II/LC3I ratio (Figure 3A and Supplemental Figure 3A). To confirm these results, we stained HASL and control mice expressing the GFP-LC3 fusion protein for 24 hours. In control muscle, a striking increase in the number of GFP-LC3–positive puncta, representing autophagic vesicles, was observed upon starvation (Figure 3B and Supplemental Figure 3B). In HASL mice, the number of puncta was higher under fed conditions, but was significantly less increased upon starvation as compared with control muscle (Figure 3B and Supplemental Figure 3B). These results confirmed that autophagy is perturbed in HASL muscle, which may rely on impaired induction and/or degradation steps.

To assess the status of the autophagic flux, mice were treated for 2 days with colchicine, a drug preventing degradation of the autophagic content. Under both fed and starved conditions, colchicine induced a major switch from LC3I to LC3II in control muscle (Figure 3C). Comparing colchicine-treated and untreated mice, we observed that the fold change in the LC3II/LC3I ratio was less in HASL muscle compared with controls, in both fed and starved conditions (Figure 3C and Supplemental Figure 3C). This result ruled out that elevated LC3II levels in fed conditions were due to increased autophagy induction in HASL muscle; accumulation of autophagic vesicles was therefore likely related to restricted degradation. Consistently, levels of the autophagosome cargo protein p62 were higher in muscle from fed mutant mice than in controls (Figure 3A). However, we detected neither p62 aggregates nor accumulation of ubiquitinated proteins in muscle from fed and starved HASL mice (Figure 3D), indicating that autophagy is only mildly affected. Similarly, distribution of lysosomal vesicles, visualized by LAMP1 immunostaining, was unchanged between 2-month-old mutant and control mice (Supplemental Figure 3D). Together, these results suggest that autophagy is slightly deregulated in DM1 muscle, which results from reduced degradation in combination with attenuated autophagy induction upon starvation.

Under fed conditions, increased amounts of p62 and LC3II were not due to abnormal transcript expression in HASL muscle (Figure 4A). Moreover, expression of the Map1lc3b, Sqstm1 (encoding p62), and Ctsl (encoding cathepsin L) genes was unchanged after 24 hours of fasting, but we observed an efficient induction of the genes upon 45 hours of starvation in both mutant and control muscles (Figure 4A and Supplemental Figure 4A). It should be noted that following prolonged starvation, autophagy induction remained weaker in mutant muscle compared with control muscle (Figure 4B and Supplemental Figure 4B). To gain further insight into autophagy deregulation, we assessed the phosphorylation state of Unc51-like kinase 1 (ULK1), as mTORC1 and AMPK phosphorylate and thereby inhibit or activate ULK1, respectively (31). Upon starvation, levels of the inactive form of ULK1 remained slightly higher in mutant muscle as compared with control muscle, while no major difference was observed for its active form (ULK1P317; Figure 4C and Supplemental Figure 4C). Interestingly, rapamycin and metformin treatments were both sufficient
to increase LC3II levels in control muscle, but did not induce autophagy in HSALR muscle (Figure 4, D and E, and Supplemental Figure 4, D and E). Hence, mTORC1/AMPK deregulation in conjunction with mTORC1/AMPK-independent mechanisms likely contributes to autophagy perturbation in HSA10 muscle.

Lastly, upon starvation, expression of the atrogenes Trim63 and Fbxo32 was similarly induced in HSA10 and control muscles (Supplemental Figure 4F). However, caspase- and trypsin-like activities associated with the proteasome system were increased in muscle from fed and starved mutant mice, compared with control animals (Supplemental Figure 4G). This is consistent with a previous report showing higher proteasome activity in muscle from a DM1 mouse model expressing 550 CTG triplets (12).

**Involvement of AMPK/mTORC1 deregulation in DM1 pathology.** To ascertain the relevance of the changes observed in HSA10 mice for DM1 pathology, we evaluated the activation state of AMPK/
mTORC1 signaling in muscle biopsies from 3 DM1 patients (P1–3) of 33, 34, and 49 years of age. There was no major difference in total and phosphorylated levels of PKB/Akt and AMPK proteins in muscle from DM1 patients compared with age-matched control individuals (C1/2 and C3–5 aged 30 and 50 years, respectively) (Figure 5A). However, the nutritive status of the patients at the time of the biopsy could not be ascertained and may have influenced the results. For this reason, we next tested the ability of DM1 human muscle cells to modulate mTORC1/AMPK signaling in response to energy and nutrient deprivation. Fibroblasts of 3 DM1 patients (DM-L1–3) were transduced with MyoD and differentiated for 10 days into myotubes, before being subjected to growth medium or to amino acid– and glucose-deprived conditions (i.e., PBS) for 3 hours. Upon deprivation, levels of the active phosphorylated forms of PKB/Akt and S6 were strongly reduced in control muscle cells; there was no major activation of AMPK in comparison with enriched conditions (Figure 5B). A similar response was observed in DM1 muscle cells, although they retained higher phosphorylation of S6 in deprived conditions compared with control cells (Figure 5B). In parallel, a major switch from LC3I to LC3II occurred in control muscle cells upon deprivation. LC3II levels were further increased in control cells treated with chloroquine, consistent with high autophagy induction in deprived cells (Figure 5C). In contrast, LC3II levels were only slightly changed when DM1 myotubes were subjected to deprivation, even in the presence of chloroquine, indicating that the autophagic flux is blocked at the induction steps (Figure 5C). Together, these data indicate that DM1 human muscle cells do not efficiently respond to nutrient/energy deprivation and display deregulation of the autophagy process.

Figure 6. AICAR markedly decreases myotonia in HSA LR mice and reduces mis-splicing in mutant muscle. (A) In vitro tetanic stimulation of EDL muscle reveals strongly increased relaxation time in HSA LR muscle. (B) Metformin (MetF) treatment does not reduce muscle late relaxation time in 4-month-old (Ctrl, n = 5; HSA LR, n = 6 Veh and 8 MetF) and 12-month-old (Ctrl, n = 3; HSA LR, n = 7 Veh and 8 MetF) HSA LR mice, as compared with vehicle-treated mutant mice. (C) Inclusion of exon 7a of the Clcn1 gene is not changed in muscle from metformin-treated (MetF) HSA LR mice, compared with vehicle-treated mice (n = 3). (D) Immunoblots for phospho- and total S6 protein reveal efficient inhibition of indirect AMPK target in muscle from control (Ctrl) and mutant mice treated with AICAR. Samples were run on the same gel but were noncontiguous. (E) AICAR treatment normalizes the time to relax of HSA LR muscle upon tetanic stimulation, compared with muscle from vehicle-treated (Veh) mutant mice. (F) Late relaxation time is significantly reduced in muscle from 2-month-old (n = 3 Ctrl and 4 HSA LR), 8-month-old (Ctrl, n = 3; HSA LR, n = 6 Veh and 7 AICAR), and 12-month-old (n = 4 Veh and 5 AICAR) HSA LR mice that were treated with AICAR, as compared with age-matched vehicle-treated (Veh) mutant mice. (G–K) End-point PCR (G) and quantitative PCR (H and I) reveal strong reduction in exon 7a inclusion of the Clcn1 gene in muscle from HSA LR mice treated with AICAR, compared with vehicle-treated (Veh) mutant mice (Ctrl, n = 3; HSA LR, n = 5 Veh and 4 AICAR [G, n = 5]). Protein levels of CLC-1 are also increased in mutant muscle from AICAR-treated mice (I and K, n = 3 Ctrl and 4 HSA LR). (L) Quantitative PCR shows similar transcript levels of Rbm3 in muscle from AICAR-treated and untreated mice (n = 3 Ctrl and 4 HSA LR). Data represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, 2-way ANOVA with Tukey’s multiple comparisons test correction (except 12M AICAR, unpaired 2-tailed Student’s t test).
Table 1. Changes in muscle cross-sectional area and tetanic forces upon treatments in HSA<sup>14</sup> and control mice

<table>
<thead>
<tr>
<th></th>
<th>Ctrl</th>
<th>AICAR</th>
<th>HSALR</th>
<th>AICAR</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CSA EDL (mm&lt;sup&gt;2&lt;/sup&gt;)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4M</td>
<td>1.69 ± 0.12</td>
<td>1.61 ± 0.07</td>
<td>2.04 ± 0.07&lt;sup&gt;B&lt;/sup&gt;</td>
<td>1.96 ± 0.02&lt;sup&gt;B&lt;/sup&gt;</td>
</tr>
<tr>
<td>12M</td>
<td>1.67 ± 0.09</td>
<td>1.50 ± 0.10</td>
<td>1.90 ± 0.06</td>
<td>1.77 ± 0.09</td>
</tr>
<tr>
<td><strong>Po (mN)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4M</td>
<td>180.94 ± 26.37</td>
<td>170.07 ± 3.91</td>
<td>193.80 ± 13.01</td>
<td>274.48 ± 16.11&lt;sup&gt;BC&lt;/sup&gt;</td>
</tr>
<tr>
<td>12M</td>
<td>226.14 ± 28.30</td>
<td>245.67 ± 16.07</td>
<td>209.59 ± 30.94</td>
<td>240.28 ± 18.95</td>
</tr>
<tr>
<td><strong>sPo (mN/mm&lt;sup&gt;2&lt;/sup&gt;)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4M</td>
<td>114.98 ± 21.53</td>
<td>111.32 ± 8.79</td>
<td>99.41 ± 7.64</td>
<td>146.46 ± 8.32&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>12M</td>
<td>137.66 ± 23.49</td>
<td>168.87 ± 20.50</td>
<td>103.78 ± 15.01</td>
<td>137.12 ± 12.41</td>
</tr>
</tbody>
</table>

CSA, cross-sectional area; M, month; Po, tetanic muscle force; sPo, specific tetanic muscle force. CSA = weight/(1.06 * length * 0.44), where 1.06 corresponds to the density of the muscle and 0.44 the correction factor for EDL muscle. AICAR, 2-month-old (n = 3 Ctrl and 4 HSALR), 8-month-old (Ctrl, n = 3; HSALR, n = 6 Veh and 7 AICAR), 12-month-old (HSALR, n = 4 Veh and 5 AICAR) mice; rapamycin, 4-month-old (Ctrl, n = 4; HSALR, n = 8 Veh and 10 Rapa), 12-month-old (Ctrl, n = 3; HSALR, n = 5 Veh and 6 Rapa) mice; AZD8055, 8-month-old (Ctrl, n = 3; HSALR, n = 5 Veh and 8 AZD) mice. Values are mean ± SEM. *P < 0.05, **P < 0.01, **P < 0.001 compared with control mice with same treatment; *P < 0.05, **P < 0.01, ***P < 0.001 compared with same genotype treated with vehicle; 2-way ANOVA with Tukey’s multiple comparisons test correction; for 12-month-old AICAR-treated mice, unpaired 2-tailed Student’s t test.

To test the relevance of autophagy changes in DM1, we looked for muscle alterations related to autophagy defects in muscle biopsies from DM1 patients and in muscle from aged HSA<sup>14</sup> mice. As previously reported (14, 35–37), vacuolated fibers were observed in muscle biopsy of 1 DM1 patient, out of the 3 examined (Figure 5D). However, in contrast to biopsies from DM1 muscle (Figure 5D). Therefore, we investigated whether AMPK normalization would have a beneficial effect on muscle function in mutant mice. As readout of the disease, we evaluated myotonia by measuring the late relaxation time of skeletal muscle (i.e., time to reduce the maximal force from 50% to 10%) after ex vivo tetanic stimulation (8). As reported previously, we observed no change in the late relaxation time of soleus muscle from HSA<sup>14</sup> mice compared with controls (Supplemental Figure 6A), whereas this parameter was strongly increased in extensor digitorum longus (EDL) mutant muscle (Figure 6A). Since AMPK activation by metformin has recently been shown to correct mis-splicing in human DM1 cells in vitro (38), 4- and 12-month-old control and HSA<sup>14</sup> mice were treated with metformin for 10 days. Despite using high doses of metformin, we observed only a limited and nonreproducible effect of the treatment on AMPK/S6 activation state in these groups of mice analyzed under basal nutritive conditions (Supplemental Figure 6B). Besides, the treatment failed to reduce the late relaxation time of EDL muscle in mutant mice (Figure 6B), and it did not modify the expression and splicing of genes affected in DM1, including Clcn1 (encoding CLC-1, chloride channel protein 1; inclusion of exon 7a) and Atp2a1 (encoding sarcoplasmic/endoplasmic reticulum Ca<sup>2+</sup>-ATPase 1; exclusion of exon 22) (Figure 6C). We further confirmed that AICAR increased phosphorylated levels of AMPK and those of its direct target acetyl-CoA carboxylase shortly after the last injection (30 minutes), while inhibition of the indirect AMPK target S6 was detected only after 2 hours in control muscle (Supplemental Figure 6D). Importantly, following tetanic stimuli, a strong and significant reduction in the late the vacuoles, and we did not observe such features in muscle from age-matched control mice (Figure 5E and Supplemental Figure 5B). Electron microscopy confirmed the presence of vacuoles in mutant mouse muscle: they were surrounded by dense, disorganized areas of contractile elements and usually limited by a single, discontinuous membrane (Supplemental Figure 5C). Together with the lysosome staining, these features argue for the presence of autophagic vacuoles in muscle from older HSA<sup>14</sup> mice. These results suggest that autophagy perturbation may contribute to the alteration of muscle tissue in DM1, but is unlikely to be a predominant feature of the disease.

AICAR, an AMPK agonist, abrogates myotonia in HSA<sup>14</sup> mice. In light of the deregulation of AMPK signaling in HSA<sup>14</sup> muscle, we investigated whether AMPK normalization would have a beneficial effect on muscle function in mutant mice. As readout of the disease, we evaluated myotonia by measuring the late relaxation time of skeletal muscle (i.e., time to reduce the maximal force from 50% to 10%) after ex vivo tetanic stimulation (8). As reported previously, we observed no change in the late relaxation time of soleus muscle from HSA<sup>14</sup> mice compared with controls (Supplemental Figure 6A), whereas this parameter was strongly increased in extensor digitorum longus (EDL) mutant muscle (Figure 6A). Since AMPK activation by metformin has recently been shown to correct mis-splicing in human DM1 cells in vitro (38), 4- and 12-month-old control and HSA<sup>14</sup> mice were treated with metformin for 10 days. Despite using high doses of metformin, we observed only a limited and nonreproducible effect of the treatment on AMPK/S6 activation state in these groups of mice analyzed under basal nutritive conditions (Supplemental Figure 6B). Besides, the treatment failed to reduce the late relaxation time of EDL muscle in mutant mice (Figure 6B), and it did not modify the expression and splicing of genes affected in DM1, including Clcn1 (encoding CLC-1, chloride channel protein 1; inclusion of exon 7a) and Atp2a1 (encoding sarcoplasmic/endoplasmic reticulum Ca<sup>2+</sup>-ATPase 1; exclusion of exon 22) (Figure 6C). We further confirmed that AICAR increased phosphorylated levels of AMPK and those of its direct target acetyl-CoA carboxylase shortly after the last injection (30 minutes), while inhibition of the indirect AMPK target S6 was detected only after 2 hours in control muscle (Supplemental Figure 6D). Importantly, following tetanic stimuli, a strong and significant reduction in the late...
relaxation time of EDL muscle was detected in 2- and 12-month-old AICAR-treated mutant mice, and myotonia was completely abrogated with AICAR in the group of 8-month-old HSALR mice (Figure 6, E and F). Normalization of the half-relaxation time (i.e., time to reduce the maximal force from 100% to 50%) of mutant muscle was also observed upon treatment (Supplemental Figure 6E). As mis-splicing of the Clcn1 gene is thought to be the primary cause of myotonia in DM1 (7, 39–41), we investigated whether the effect of AICAR was related to changes in Clcn1 splicing. By end-point PCR, a significant improvement of splicing was detected upon AICAR treatment (Figure 6G). We confirmed by quantitative PCR that the expression of the mis-spliced Clcn1 transcript (containing exon 7a) was strongly reduced in muscle from AICAR-treated HSALR mice, while overall transcript levels of Clcn1 were unchanged compared with those in untreated mutant mice (Figure 6, H and I). Furthermore, AICAR led to a slight increase in CLC-1 protein levels in mutant muscle (Figure 6, J and K). It is worth noting that AICAR did not change splicing of the Atp2a1 and Camk2b genes in HSA	extsuperscript{LR} muscle (Supplemental Figure 6, F and G). Moreover, we did not detect any reduction in transcript levels of Rhb3, encoding RNA-binding protein 3 (Figure 6L), previously suggested to mediate the effect of AMPK activation on splicing (38).

Besides its effect on myotonia, we wondered whether AICAR treatment would change muscle force in mutant mice. As initially reported (5), we detected neither muscle wasting nor reduction in total twitch (Pt) and tetanic (Po) muscle forces in HSA	extsuperscript{LR} mice compared with controls (Table 1 and Supplemental Table 1). Nonetheless, as cross-sectional area [CSA: mass/(density * length * correction factor)] of EDL muscle was increased in mutant mice, specific muscle forces (sPt and sPo), representative of the contractile capacity of the myofibers, were reduced in HSA	extsuperscript{LR} muscle, compared with control animals (Table 1 and Supplemental Table 1). Upon AICAR treatment, we observed that both total and specific forces of EDL muscle were increased in 2-month-old HSA	extsuperscript{LR} and control mice, but not in older mice (Table 1 and Supplemental Table 1).

Altogether, these results indicate that targeting AMPK activation by AICAR improves muscle function in HSA	extsuperscript{LR} mice by reducing myotonia and potentially increasing muscle force, at least in part, through splicing correction.

Rapamycin treatment improves muscle function in HSA	extsuperscript{LR} mice. Based on the abnormal activation of mTORC1 signaling detected in HSA	extsuperscript{LR} muscle, we wondered whether indirect mTORC1 inhibition would improve muscle function in mutant mice. To this purpose, we subjected 4- and 12-month-old mice to rapamycin treatment for 7 and 10 days, respectively. Rapamycin treatment efficiently inhibited mTORC1 signaling, as shown by reduced phospho-S6 levels in muscle from control and HSA	extsuperscript{LR} mice (Supplemental Figure 7A). Rapamycin did not affect muscle half-relaxation time (Supplemental Figure 7B), but significantly reduced the late relaxation time of EDL muscle from 4- and 12-month-old HSA	extsuperscript{LR} mice (Figure 7, A and...
B). Moreover, we detected a significant increase in total and specific muscle forces in young rapamycin-treated mutant mice compared with vehicle-treated animals. Forces remained unchanged upon treatment in older mice (Table 1 and Supplemental Table 1).

To test whether the effect of rapamycin on muscle function relied on splicing improvement, we assessed Clcn1 mis-splicing (i.e., exon 7a inclusion) by quantitative PCR. Interestingly, rapamycin affected neither Clcn1 splicing (Figure 7C) nor the overall transcript expression of the gene (Figure 7D) in mutant muscle. Consistently, splicing of the Atp2a1 gene was also not restored in rapamycin-treated HSALR mice (Supplemental Figure 7C). Together, these data suggest that mTORC1 inhibition by rapamycin is sufficient to improve muscle function in HSALR mice likely through splicing-independent mechanisms.
Since rapamycin has been shown to impact on channel function (e.g., ryanodine receptor 1, RyR1) via its binding to FKBP12, we wondered whether mTORC1 inhibition or the drug itself mediated the effect of the treatment on myotonia. Hence, control and HSAKT mice were treated for 10 days with AZD8055, an ATP-competitive inhibitor of mTORC1. We confirmed that AZD8055 strongly decreased phospho-S6 levels in control and mutant muscle, while the activation state of AMPK remained unchanged (Figure 7E). In contrast to rapamycin, AZD8055 had no effect on late relaxation time of mutant muscle (Figure 7F). Nonetheless, total and specific forces of EDL muscle were increased in AZD8055-treated mutant mice, as observed with rapamycin (Table 1 and Supplemental Table 1). Together, these results indicate that mTORC1 inhibition may ameliorate the contractile capacity of muscle in HSAKT mice and suggest that improvement of muscle relaxation upon rapamycin and AICAR treatments may be independent of mTORC1.

**AICAR, but not rapamycin, leads to nuclear foci dispersion in HSAKT muscle.** To further understand the beneficial effect of AICAR and rapamycin in HSAKT mice, we investigated whether the treatments improved muscle function by affecting the properties of the diseased muscle. First, we did not observe major changes in the histopathology of HSAKT muscle upon 7-day AICAR or 10-day rapamycin treatment, compared with untreated conditions (Figure 8A). Notably, vacuoles remained present in muscle fibers from 12-month-old AICAR- or rapamycin-treated HSAKT mice (Figure 8A), indicating that the treatments were not sufficient to reverse muscle alterations related to impaired autophagy in aging mice. As no myotonia was detected in the slow, soleus muscle of HSAKT mice and as AICAR and rapamycin were previously shown to alter muscle fiber types (42, 43), we tested whether changes in muscle function upon treatments were related to modification of muscle metabolic and contractile capacities. By reduced nicotinamide adenine dinucleotide (NADH) staining, we first observed that the overall oxidative property of TA muscle was unchanged in AICAR- and rapamycin-treated mutant mice, compared with untreated animals (Figure 8B). Immunostaining against type I, IIA/X, and IIB myosin heavy chains (MHCs) was then conducted in TA muscle from HSAKT and control mice to identify changes in muscle contractile properties upon treatment. Few type I fibers were present in all the muscles analyzed (data not shown). Mutant muscle displayed a switch to slower fibers (i.e., increased and reduced proportion of IIA and IIB fibers, respectively) compared with control muscle (Figure 8C). However, upon AICAR or rapamycin, there was no significant change in the proportion of the different fiber types in comparison with vehicle-treated mice (Figure 8C).

Since aggregation of (CUG)n-expanded RNA in nuclear foci is a histological hallmark in DM1 diseased muscle, we next wondered whether the treatments affected their accumulation in HSAKT muscle. To this purpose, we performed FISH using a CAG_{10} DNA probe on TA muscle sections from mutant untreated and treated mice. Numerous foci were observed in HSAKT muscle, while none were detected in control muscle (Figure 8D). Interestingly, the number of nuclei showing foci was significantly decreased in muscle from AICAR-treated mutant mice, while no change was observed with rapamycin (Figure 8D). Moreover, foci appeared more diffuse in positive nuclei from mutant muscle upon AICAR treatment, compared with untreated conditions (Figure 8D). Altogether, these results indicate that changes in muscle metabolic and contractile properties do not account for the beneficial effect of the short treatments applied to HSAKT mice, while reduced muscle pathology upon AICAR-mediated acute AMPK activation likely involves nuclear foci dispersion in the mutant muscle.

**Discussion**

The pathogenic mechanisms underlying DM1 disease are still not well understood, and most investigations so far have focused on splicing defects caused by mRNA toxicity. In this study, we uncovered that in DM1, the AMPK and the mTORC1 pathways are deregulated and that the autophagic flux is perturbed in skeletal muscle. Most importantly, we established that AICAR and rapamycin, which interfere with AMPK/mTORC1 signaling, ameliorate DM1 muscle function (Figure 9).

AMPK signaling and PKB/Akt-mTORC1 signaling are central metabolic pathways in muscle cells, and their deregulation has been related to muscle alterations and disease (27, 32, 44).
We found that DM1 muscle shows an altered response to energy/nutrient-deprived conditions, with impaired AMPK activation and abnormal activation of mTORC1 signaling. Although we have not studied the upstream mechanisms involved in this deregulation, mis-splicing-dependent CaMKII deficiency could well account for the limited AMPK activation in DM1 muscle (21, 23–26). Interestingly, Jones et al. recently reported increased GSK3β levels and activity in HSA18 muscle (45), which may also contribute to the perturbation of AMPK in DM1 muscle (46). In parallel, AMPK constitutes an upstream regulator of mTORC1 (47), and its deregulation could thus be responsible for abnormal mTORC1 activation in DM1 muscle cells. Nonetheless, as we did not detect changes in 4E-BP1 levels or mTOR phosphorylation in mutant muscle, evidence that the state of mTORC1 is modified in DM1 muscle and not only the activation of its downstream axis p70S6K/S6 is missing. Previous reports suggested that mTORC1 is inhibited in DM1 human neural and muscle cells (14, 17), although results were only obtained in vitro and the underlying mechanisms have not been investigated. On the basis of the abnormal splicing and protein trafficking of the insulin receptor in metabolic tissues in DM1 (15, 16), it has also been hypothesized that PKB/Akt–mTORC1 may be less responsive to insulin. However, results regarding the activation state of PKB/Akt signaling in DM1 human muscle biopsies or cells are conflicting (18, 19). In our experiments, we did not detect changes in PKB/Akt activation or in the expression of Insr in HSA18 muscle, suggesting that AMPK/mTORC1 deregulation is independent of insulin receptor deficiency.

Autophagy as a major catabolic process essential for proteostasis has also been suggested to contribute to muscle alterations in DM1 (48). The involvement of autophagy in DM1 was largely deduced from the presence of autophagic vesicles and/or accumulation of autophagic markers in DM1 cells, but usually without dynamic measurement of the autophagic flux (13, 14, 17, 19, 36, 37, 49). In our study, we combined several methods to establish that mild changes in autophagic markers in muscle from HSA18 mice are caused by autophagic flux limitation during the degradation steps. Further, we showed that even prolonged starvation did not fully induce autophagy in mutant muscle. We hypothesize that AMPK- and mTORC1-independent mechanisms contribute to autophagy perturbation, as rapamycin and metformin were not sufficient to normalize the flux in HSA18 mice. Although this autophagy deregulation may contribute to muscle atrophy in DM1, it is unlikely to be the main pathogenic event, as autophagic features were scarce in DM1 muscle biopsies, compared with diseases primarily related to autophagy defects, such as vacuolar myopathies.

Importantly, we identified that AMPK/mTORC1 deregulation likely contributes to alteration of muscle function in DM1. Myotonia, which is due to membrane hyperexcitability, is thought to be caused primarily by mis-splicing and thereby deficiency in the CLC-1 (5, 7, 39, 41). In contrast to a recent report studying cultured human DM1 cells (38), we did not find any effect of metformin on the mis-splicing of DM1-affected genes or on the severe myotonia observed in HSA18 mice. While we cannot rule out that changes in dosage and administration may lead to different results, much higher concentrations may be required to efficiently stimulate AMPK in rodent muscle tissue. Although metformin is commonly used to treat diabetes, clinical evaluation of its effect on muscle function in DM1 patients is lacking. In contrast to metformin, we found a profound effect of AICAR, a more potent AMPK agonist. AICAR led to a strong reduction of myotonia in HSA18 mice, which correlated with improved splicing of the Clcn1 gene and increased protein levels of the channel. While AMPK activation was related to repression of the RNA-binding protein Rbm3 in vitro, Rbm3 expression was unchanged in HSA18 muscle upon AICAR treatment. As we observed dispersion of the nuclear foci formed by the (CUG)n-expanded RNA aggregation after AICAR treatment, the effect of AMPK activation on splicing may be mediated by its interaction with other RNA-binding proteins, such as hnrNP H, which were implicated in foci stability in DM1 (50, 51). Hence, one may argue that AMPK deregulation likely contributes to pathogenesis in DM1 muscle by perturbing RNA-binding proteins and thereby accentuating foci stability and mis-splicing events (52–54). Notably, we cannot rule out that amelioration of muscle relaxation also relies on splicing-independent mechanisms. In particular, changes in sodium- and calcium-activated potassium channels or in Ca2+ homeostasis, which have also been suggested to contribute to myotonia in DM1 (55–60), may mediate some of the observed effect. Consistently, AMPK has been shown to modulate chloride and potassium channels in several cell types, including cardiomyocytes (61, 62). Such mechanisms may also contribute to the beneficial effect of rapamycin, as it occurs in the absence of splicing changes. Rapamycin could influence intracellular calcium mobilization by dissociating FKBP3 (FK506-binding protein) from RyR1, thereby modifying channel activity (63–65). Although AZD8055-dependent mTORC1 inhibition did not improve muscle relaxation, further investigations are required to rule out the involvement of mTORC1 signaling in myotonia reduction, given the complexity of the signaling.

While muscle weakness is observed in DM1 patients, it was initially not reported in HSA18 mice (5). Consistently, in our study, total muscle force was not affected in mutant mice but we observed reduced specific strength of EDL muscle in HSA18 mice. Both specific and total muscle forces were increased upon AICAR, rapamycin, and AZD8055 treatments in young mutant mice, which may be mediated by mTORC1 inhibition as the signaling was shown to modulate Ca2+ homeostasis and excitation-contraction coupling in skeletal muscle (66). Myotonia reduction and increase in muscle force were not caused by modified metabolic and contractile properties of the mutant muscle upon the applied short-term treatments. However, one can hypothesize that these changes expected upon long-term administration of these drugs (i.e., switch toward slower fibers) may further positively affect DM1 muscle function.

In conclusion, we identified that deregulation of AMPK/mTORC1 signaling, together with mild autophagy perturbation, contributes to DM1-associated muscle alterations. We showed that treatments targeting the AMPK/mTORC1 imbalance are beneficial for muscle function, though to varying degrees. Whether alternative AMPK/mTORC1-targeting compounds, as well as changes in the dosage, administration mode, or treatment duration, may further improve muscle function remains to be investigated. As the drugs used in our study can target the pathways body-wide, they may also be beneficial in other tissues and thus may represent new treatment options for DM1.
Methods

Mice. Homozygous mice of the mouse line LR20b carrying about 250 (CTG) repeats within the HSA transgene (HSA<sup>LR</sup>) were obtained from Thornton and colleagues (University of Rochester Medical Center, Rochester, New York, USA) (5). Mice of the corresponding background strain (FVB/N) were used as control. GFP-LC3 HSA<sup>L</sup>R and GFP-LC3 FVB/N mice were obtained by crossing of GFP-LC3-expressing mice (20) with HSA<sup>L</sup>R or FVB/N mice. Mice were genotyped for HSA<sup>L</sup>R transgenes by quantification of ACTA1 levels normalized to endogenous actin (mouse Acta1) in genomic DNA. Mice were maintained in a conventional specific-pathogen-free facility with a fixed light cycle (23°C, 12-hour dark-light cycle). Mice were injected i.p. with colchicine (Sigma-Aldrich; 0.4 mg/kg) for 2 days, rapamycin (LC Laboratories) for 1 day (4 mg/kg) or 7 or 10 days (2 mg/kg), AICAR (Toronto Research Chemicals; 500 mg/kg) for 7 days, or AZD8055 (LC Laboratories; 10 mg/kg) for 10 days. Mice were treated with metformin (Sigma-Aldrich; 300 mg/kg) by gavage for 5 or 10 days. For starvation experiments, mice were sacrificed after 12 hours of food deprivation followed by 4 hours of free access to food (fed), or after 24 or 45 hours of food deprivation but free access to water (starved). In vitro force measurement of EDL and soleus muscles was conducted as previously described (32). Half- and late relaxation times were calculated according to Moyer et al. (8).

Human muscle cells and biopsy samples. Muscle biopsies frozen in nitrogen-cooled isopentane were from 3 DM1 patients, aged 33, 34, and 49 years, and from an IBM patient who was analyzed and compared with 5 control muscle samples from age-matched individuals showing no clinical signs of DM1 and normal muscle histology. MyoD-transduced fibroblasts from control individuals and patients were cultured in growth medium (DMEM, 10% FBS, 50 μg/ml gentamicin) at 37°C under 5% CO<sub>2</sub>. At confluence, transduction into myoblasts was induced by differentiation medium (DMEM, 50 μg/ml gentamicin, 3 μg/ml doxycycline hyclate, 10 μg/ml human recombinant insulin) (67). Myotubes obtained after 10 days were incubated for 3 hours in growth medium (refed), PBS (starved), or PBS supplemented with chloroquine (100 μM).

Western blotting. Cell pellets and muscles powdered in liquid nitrogen were lysed in cold RIPA’ buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1% Triton X, 10% glycerol, phosphatase and protease inhibitors). Following dosage (BCA Protein Assay, Sigma-Aldrich), proteins were separated on SDS-polyacrylamide gels and transferred to nitrocellulose membrane. Blots were blocked in TBS, 3% BSA, 0.1% Tween-20, and incubated overnight at 4°C with primary antibodies, then for 2 hours with appropriate secondary fluorescent antibodies (Invitrogen), mounted in Vectorshied medium (Vector), and observed with a Leica fluorescent microscope.

GFP-LC3 puncta analysis. For GFP-LC3 detection, mice were perfused with 4% PFA, and muscles were incubated in 30% sucrose overnight. Cryosections were washed and mounted. Images were recorded using a Leica confocal microscope with ×63 or ×100 objectives. The number of GFP-LC3 puncta was counted on the 3D reconstructed images with Imaris (version 8.1.2) software. Seven to twelve image stacks were quantified for each muscle, and the average number of GFP-LC3 puncta per volume unit defined within a single fiber (20.8 × 20.8 × 6.5 μm<sup>3</sup>) was used for statistical analyses. All GFP quantifications were done in a blinded way.

Fluorescence in situ hybridization. FISH was conducted on muscle cryosections as previously described by Batra et al. (68), using a Cy3-CAG<sub>40</sub> DNA probe. Nuclear foci were observed with a Leica confocal microscope with ×40 and ×100 objectives.

Statistics. Quantitative data are displayed as mean ± SEM of independent experiments, with n (number of independent experiments) ≥ 3. Statistical analysis of values was performed using Student’s t test or 2-way ANOVA test with Tukey’s multiple comparisons test correction, with a 0.05 level of confidence accepted for statistical significance.

Study approval. Muscle biopsies from DM1 patients were obtained from the Neuromuscular Tissue Bank (Department of Neurosciences, University of Padova, Padova, Italy) through the Telethon Network of Genetic Biobanks and the EuroBioBank, in accordance with European recommendation and Italian legislation on ethics. Control and IBM human muscle biopsies were from the Department of Pathology, University Hospital Basel (Basel, Switzerland); their use was approved by the Ethical Committee of the University Hospital Basel. Human fibroblast cell lines were obtained from the platform for immortalization of human cells at the Institut de Myologie (Paris, France). Fibroblasts derived from skin biopsies were obtained from the MyoBank-AFM bank of tissues for research at the Institut de Myologie, a partner in the European Union network EuroBioBank, in accordance with European recommendation and French legislation on ethics. All animal studies were performed in accordance with the European Union guidelines for animal care and approved by the Veterinary Office of the Canton of Basel city (application number 2601).

Author contributions

MB and PC performed most of the experiments, analyzed the data, and wrote the paper with input from all authors. NR, KC, TW, CE, and BE conducted quantitative PCR and Western blot analyses, GFP-LC3 quantification, muscle dissection, cryosections and inorganic staining, and electron microscopy analyses, respectively. SF and CA provided human muscle biopsies. DF developed and provided transduced fibroblasts from DM1 patients. MAR and MS helped conceive the project and edited the manuscript. MS secured funding. PC designed and directed the research project.
We thank C.A. Thornton for the generous gift of HSA LR mice, and J. Hench and G. Schwieghauer (Institute of Pathology, University of Basel, University Hospital Basel) for their help in preparing electron microscopy samples. We are grateful to S. Lin (Biozentrum, University of Basel) for his technical expertise on muscle force measurement and Iamiris software, and to J. Kinter and L. Tintignac (Neuromuscular Research Group, University of Basel, University Hospital Basel) for their constructive comments on the project. We also thank the platform for immortalization of human cells from the Institut de Myologie (Paris, France) for providing human transduced fibroblasts. MHC antibodies, developed by H.M. Blau and S. Schiaffino, were obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, Iowa, USA). This work was supported by EuroBioBank and Telethon Network of Genetic Biobanks (grant GTB 12001D to CA), the University of Basel and University Hospital Basel (MS), the University of Basel–Stadt and Basel-Landschaft (MAR), the Neuromuscular Research Association Basel (MS, PC), the Swiss Foundation for Research on Muscle Diseases (MAR, MS), and the Swiss National Science Foundation (PC, MS).

Address correspondence to: Perrine Castets, Biozentrum, University of Basel, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland. Phone: 41.61.260.22.25; E-mail: perrine.castets@unibas.ch. Or to: Michael Sinnreich, Neuromuscular Research Group, Departments of Neurology and Biomedicine, University of Basel, University Hospital Basel, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland. Phone: 41.61.265.25.25; E-mail: michael.sinnreich@unibas.ch.


